Find in Library

Diabetes mellitus (DM) is one of the most common chronic diseases worldwide. According to the International Diabetes Federation (IDF), the number of adult patients (20-79 years) will reach 552 million people by 2030 globally[1]. Achieving and maintaining a stable blood glucose concentration closest to the physiological standards is the main goal of DM therapy[2]. Insulin therapy is the only effective treatment for diabetes mellitus type 1; in addition, many people with DM 2 and other types one day reach a point at which insulin becomes the only way to achieve the goal of treatment. Continuous subcutaneous insulin infusion (CSII) is a method of insulin delivery into the patient's organism, and an alternative to multiple injections.